Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Prognostic Factors after Nonmyeloablative Allogeneic Stem Transplantation (NST) in Chronic Lymphocytic Leukemia (CLL): Expression of P53 May Not Predict Survival.

Issa Khouri, Roland L Bassett, Yvonne Hsu, Timothy Dickason, Sandra Acholonu, Robyn Harrell, Grace-Julia Okoroji, Leandro de Padua Silva, Martin J. Korbling, Amin M. Alousi, Chitra Hosing, Uday Popat, Sergio A. Giralt, Partow Kebriaei, Muzaffar H. Qazilbash, M.D., Celina Ledesma, Michael J. Keating, MB, BS, Richard E. Champlin, Carlos Bueso-Ramos

Blood (2008) 112 (11): 1128.

https://doi.org/10.1182/blood.V112.11.1128.1128

Published: 2008

Journal Articles

Importance of PI3 Kinase Family for Crosstalk between Chronic Lymphocytic Leukemia B Cells and the Stromal Microenvironment: Therapeutic Implications.

Matthias T.W. Niedermeier, PhD, Justyna Rawluk, MD, Zachary Knight, PhD, Kevan Shokat, PhD, William G. Wierda, MD, PhD, Michael J. Keating, MB, BS, Jan A. Burger, MD, PhD

Blood (2007) 110 (11): 1125.

https://doi.org/10.1182/blood.V110.11.1125.1125

Published: 2007

Journal Articles

Update of Experience with Fludarabine, Cyclophosphamide, Mitoxantrone Plus Rituximab (FCM-R) in Frontline Therapy for Chronic Lymphocytic Leukemia (CLL).

Stefan Faderl, MD, William Wierda, MD, PhD, Alessandra Ferrajoli, MD, Susan O’Brien, MD, Farhad Ravandi, MD, Hagop M. Kantarjian, MD, Brandi L. Showalter, RN, Susan Lerner, RN, Michael J. Keating, MB, BS

Blood (2007) 110 (11): 627.

https://doi.org/10.1182/blood.V110.11.627.627

Published: 2007

Journal Articles

Lenalidomide Is Active in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Carrying Unfavorable Chromosomal Abnormalities.

Alessandra Ferrajoli, MD, Michael J. Keating, MB, BS, William G. Wierda, MD, PhD, Susan M. O’Brien, MD, Swaminathan Padmanabhan, MD, Myron S. Czuczman, MD, Asher A. Chanan-Khan, MD

Blood (2007) 110 (11): 754.

https://doi.org/10.1182/blood.V110.11.754.754

Published: 2007

Journal Articles

The Synthetic Hest Shock Protein (Hsp) 90 Inhibitor EC141 Induces Degradation of the Bcr-Abl p190 Protein and Apoptosis of Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (ALL) Cells.

Alessandra Ferrajoli, MD, Yongtao Wang, MD, Susan M. O’Brien, MD, Stefan H. Faderl, MD, David M. Harris, BS, Quin Van, BS, Inbal Hallevi, PhD, Zhiming Liu, BS, Patricia E. Koch, MS, John Sensintaffar, MS, Francis Burrows, PhD, Hagop M. Kantarjian, MD, Michael J. Keating, MB, BS, Zeev Estrov, MD

Blood (2007) 110 (11): 2784.

https://doi.org/10.1182/blood.V110.11.2784.2784

Published: 2007

Journal Articles

Fludarabine, Cyclophosphamide, Mitoxantrone Plus Rituximab (FCM-R) as Frontline Therapy for CLL: Results of a Phase 2 Study.

Stefan Faderl, MD, William G. Wierda, MD PhD, Susan O’Brien, MD, Alessandra Ferrajoli, MD, Farhad Ravandi-Kashani, MD, Michelle Detry, PhD, Hagop M. Kantarjian, MD, Brandi O’Neal, RN, Michael J. Keating, MB BS

Blood (2006) 108 (11): 2836.

https://doi.org/10.1182/blood.V108.11.2836.2836

Published: 2006

Journal Articles

Self-Administered, Subcutaneous (SQ) Alemtuzumab To Eliminate Residual Disease in Patients (pts) with CLL.

William G. Wierda, MD, PhD, Thomas J. Kipps, MD, Michael J. Keating, MB BS, Jennifer R. Brown, MD PhD, John G. Gribben, MD DSC, M.L. Browning, RN, L. Rassenti, PhD, A. Greaves, BS, Donna Neuberg, ScD, Susan M. O’Brien, MD

Blood (2006) 108 (11): 2839.

https://doi.org/10.1182/blood.V108.11.2839.2839

Published: 2006

Journal Articles

The Combination of Alemtuzumab [Continuous Intravenous Infusion (civ) Followed by Subcutaneous Injection (sc)] Plus Rituximab Has Activity in Patients (pts) with Relapsed Chronic Lymphocytic Leukemia (CLL).

Stefan Faderl, MD, Alessandra Ferrajoli, MD, William G. Wierda, MD PhD, Susan O’Brien, MD, Farhad Ravandi-Kashani, MD, Luis Fayad, MD, Deborah Thomas, MD, Hagop Kantarjian, MD, Mary L. Browning RN, Michael J. Keating MB, BS

Blood (2006) 108 (11): 2827.

https://doi.org/10.1182/blood.V108.11.2827.2827

Published: 2006

Journal Articles

Membrane-Stable, Humanized CD154 Gene Therapy for Patients with CLL.

William G. Wierda, MD, PhD, Susan M. O’Brien, MD, R.A. Aguillon, MD, Januario Castro, MD, John McMannis, PhD, C. Prussak, PharmD, Thomas J. Kipps, MD, Michael J. Keating, MB, BS

Blood (2006) 108 (11): 2104.

https://doi.org/10.1182/blood.V108.11.2104.2104

Published: 2006

NARROW

Prognostic Factors after Nonmyeloablative Allogeneic Stem Transplantation (NST) in Chronic Lymphocytic Leukemia (CLL): Expression of P53 May Not Predict Survival.

Importance of PI3 Kinase Family for Crosstalk between Chronic Lymphocytic Leukemia B Cells and the Stromal Microenvironment: Therapeutic Implications.

Update of Experience with Fludarabine, Cyclophosphamide, Mitoxantrone Plus Rituximab (FCM-R) in Frontline Therapy for Chronic Lymphocytic Leukemia (CLL).

Lenalidomide Is Active in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Carrying Unfavorable Chromosomal Abnormalities.

The Synthetic Hest Shock Protein (Hsp) 90 Inhibitor EC141 Induces Degradation of the Bcr-Abl p190 Protein and Apoptosis of Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (ALL) Cells.

Fludarabine, Cyclophosphamide, Mitoxantrone Plus Rituximab (FCM-R) as Frontline Therapy for CLL: Results of a Phase 2 Study.

Self-Administered, Subcutaneous (SQ) Alemtuzumab To Eliminate Residual Disease in Patients (pts) with CLL.

The Combination of Alemtuzumab [Continuous Intravenous Infusion (civ) Followed by Subcutaneous Injection (sc)] Plus Rituximab Has Activity in Patients (pts) with Relapsed Chronic Lymphocytic Leukemia (CLL).

Membrane-Stable, Humanized CD154 Gene Therapy for Patients with CLL.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only